{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:19:09Z","timestamp":1787980749215,"version":"build-2784847793"},"reference-count":38,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of lymphoma, yet many patients relapse. Several prognostic markers have been associated with CAR T-cell outcomes, such as tumor burden, response to bridging chemotherapy, and laboratory parameters at the time of lymphodepletion or infusion. The effect of cancer cachexia and weight loss before CAR T cells on toxicity and outcomes is not well understood. Here, we present a retrospective single-institution cohort study of 259 patients with lymphoma treated with CAR T cells between 2017 and 2023. We observed that patients with &amp;gt;5% decrease in their body mass index in the 3\u00a0months preceding CAR T-cell treatment (weight loss group; all meeting one of the commonly accepted definitions of cancer cachexia) had higher disease burden and inflammatory parameters (C-reactive protein, ferritin, interleukin-6, and tumor necrosis factor \u03b1) at the time of lymphodepletion and CAR T-cell infusion. Patients with weight loss experienced higher rates of grade 3+ neurotoxicity and early hematotoxicity, but those effects were not seen upon multivariable adjustment. However, in both univariate and multivariable analysis, patients with weight loss had worse response rates, overall survival, and event-free survival, indicating that weight loss is an independent poor prognostic factor. Our data suggest that weight loss in the 3\u00a0months preceding CAR T-cell therapy represents a worrisome \u201calarm signal\u201d and a potentially modifiable factor, alongside tumor burden and inflammation, and warrants further investigation in patients treated with CAR T-cell therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014555","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T21:58:27Z","timestamp":1730239107000},"page":"151-161","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-8006","authenticated-orcid":false,"given":"Yannis K.","family":"Valtis","sequence":"first","affiliation":[{"name":"1Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Devlin","sequence":"additional","affiliation":[{"name":"2Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[{"name":"3Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[{"name":"3Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"4Department of Medicine III\u2013Hematology\/Oncology, LMU University Hospital, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Corona","sequence":"additional","affiliation":[{"name":"3Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2201-3091","authenticated-orcid":false,"given":"Alejandro","family":"Luna De Abia","sequence":"additional","affiliation":[{"name":"5Adult Bone Marrow Transplantation Unit, Hematology Service, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-3415","authenticated-orcid":false,"given":"Alfredo","family":"Rivas-Delgado","sequence":"additional","affiliation":[{"name":"3Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0212-2135","authenticated-orcid":false,"given":"Efrat","family":"Luttwak","sequence":"additional","affiliation":[{"name":"6Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2192-9930","authenticated-orcid":false,"given":"Giulio","family":"Cassanello","sequence":"additional","affiliation":[{"name":"3Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"7Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Landego","sequence":"additional","affiliation":[{"name":"3Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"8Department of Internal Medicine, Max Rady Faculty of Health Sciences, Section of Medical Oncology and Hematology, University of Manitoba, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-4185","authenticated-orcid":false,"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[{"name":"9Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Bedmutha","sequence":"additional","affiliation":[{"name":"10Department of Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7169-9275","authenticated-orcid":false,"given":"Alexander","family":"Boardman","sequence":"additional","affiliation":[{"name":"1Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"6Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"5Adult Bone Marrow Transplantation Unit, Hematology Service, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[{"name":"5Adult Bone Marrow Transplantation Unit, Hematology Service, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"5Adult Bone Marrow Transplantation Unit, Hematology Service, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"},{"name":"11Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"6Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"6Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":false,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[{"name":"12Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[{"name":"1Cell Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"issue":"1","key":"2025011416261278100_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"13","key":"2025011416261278100_bib2","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025011416261278100_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2025011416261278100_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-024-01540-x","article-title":"Conventional and novel [18F]FDG PET\/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma","volume":"17","author":"Leithner","year":"2024","journal-title":"J\u00a0Hematol Oncol"},{"issue":"2","key":"2025011416261278100_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacobini","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"2025011416261278100_bib6","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2025011416261278100_bib7","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2025011416261278100_bib8","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 1","key":"2025011416261278100_bib9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood-2023-173798","article-title":"An inflammatory biomarker signature reproducibly predicts CAR-T treatment failure in patients with aggressive lymphoma across the Zuma Trials Cohorts","volume":"142","author":"Raj","year":"2023","journal-title":"Blood"},{"issue":"17","key":"2025011416261278100_bib10","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2025011416261278100_bib11","doi-asserted-by":"crossref","first-page":"e000097","DOI":"10.1136\/bmjgast-2016-000097","article-title":"Cachexia in cancer: what is in the definition?","volume":"3","author":"Vanhoutte","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"issue":"5","key":"2025011416261278100_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an International Consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025011416261278100_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"issue":"3","key":"2025011416261278100_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/hon.3002","article-title":"Host-related factors and cancer: malnutrition and non-Hodgkin lymphoma","volume":"40","author":"Mancuso","year":"2022","journal-title":"Hematol Oncol"},{"issue":"1","key":"2025011416261278100_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.18054","article-title":"Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"197","author":"Roy","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"2025011416261278100_bib16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-22-0487","article-title":"Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy","volume":"11","author":"Rejeski","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"2025011416261278100_bib17","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3324\/haematol.2021.280189","article-title":"Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies","volume":"107","author":"Dos Santos","year":"2022","journal-title":"Haematologica"},{"key":"2025011416261278100_bib18","author":"CDC","year":"2022"},{"key":"2025011416261278100_bib19","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/S2152-2650(23)02103-1","article-title":"P-486 clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma","volume":"23","author":"Thirugnanasambandam","year":"2023","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"5","key":"2025011416261278100_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025011416261278100_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2025011416261278100_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT Consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025011416261278100_bib23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41409-024-02278-3","article-title":"Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity","volume":"59","author":"Liang","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"2025011416261278100_bib24","article-title":"(P1440) implications of CAR T cell referral and apheresis delays on outcomes and toxicity in lymphoma patients [abstract]","author":"Boardman","year":"2024","journal-title":"European Hematology Society (EHA) conference"},{"issue":"5","key":"2025011416261278100_bib25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41577-021-00624-w","article-title":"The interplay of immunology and cachexia in infection and cancer","volume":"22","author":"Baazim","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2025011416261278100_bib26","doi-asserted-by":"crossref","first-page":"112462","DOI":"10.1016\/j.nut.2024.112462","article-title":"Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients","volume":"124","author":"Li","year":"2024","journal-title":"Nutrition"},{"issue":"7640","key":"2025011416261278100_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"key":"2025011416261278100_bib29","doi-asserted-by":"crossref","first-page":"726257","DOI":"10.3389\/fonc.2021.726257","article-title":"Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"2025011416261278100_bib30","doi-asserted-by":"crossref","first-page":"340.e1","DOI":"10.1016\/j.jtct.2021.01.006","article-title":"Body weight loss before allogeneic hematopoietic stem cell transplantation predicts survival outcomes in acute leukemia patients","volume":"27","author":"Tamaki","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2025011416261278100_bib31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jamaoto.2024.1568","article-title":"Obesity and survival after immune checkpoint inhibition for head and neck squamous cell carcinoma","volume":"150","author":"Mastrolonardo","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"1","key":"2025011416261278100_bib32","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1186\/s12885-023-11512-y","article-title":"Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"2025011416261278100_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41409-023-02154-6","article-title":"The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party","volume":"59","author":"Gj\u00e6rde","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2025011416261278100_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-021-00515-2","article-title":"The impact of obesity and body weight on the outcome of patients with relapsed\/refractory large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"11","author":"Wudhikarn","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2025011416261278100_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s40472-023-00395-4","article-title":"Prehabilitation in adult solid organ transplant candidates","volume":"10","author":"Quint","year":"2023","journal-title":"Curr Transplant Rep"},{"issue":"7","key":"2025011416261278100_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11912-020-00932-9","article-title":"Prehabilitative exercise for the enhancement of physical, psychosocial, and biological outcomes among patients diagnosed with cancer","volume":"22","author":"Lee","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"2025011416261278100_bib37","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/0284186X.2023.2178326","article-title":"Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT Pilot Randomised Controlled Trial","volume":"62","author":"McCourt","year":"2023","journal-title":"Acta Oncol"},{"issue":"7","key":"2025011416261278100_bib38","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2025011416261278100_bib39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2023-180205","article-title":"Itacitinib for the prevention of immune effector cell therapy-associated cytokine release syndrome: results from the phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort","volume":"142","author":"Frigault","year":"2023","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/151\/2349999\/blooda_adv-2024-014555-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/151\/2349999\/blooda_adv-2024-014555-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T16:26:30Z","timestamp":1736871990000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/1\/151\/525819\/Cancer-cachexia-and-weight-loss-before-CAR-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014555","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}